Disclaimer for the US market

The products and information provided on this website are intended for healthcare professionals. These products are not for sale or distribution in the United States and statements made regarding these products have not been evaluated by the U.S. Food and Drug Administration (FDA). The efficacy of these products has not been confirmed by FDA-approved research and these products are therefore not intended to diagnose, treat, cure or prevent any disease. All information presented here is for general information purposes only and not meant as a substitute for or alternative to advice from healthcare practitioners. The Federal Food, Drug and Cosmetic Act requires this notice.

Neither the Company nor its representatives is providing any medical advice, and none should be inferred, from any ideas, suggestions, testimonials or other information set forth on this website or in other Company materials or provided over the phone, in the mail, in product packaging, or in email correspondence. This website may contain links to third-party websites. The Company provides these links as a convenience only and does not endorse any of these sites. The Company is not responsible for the content of, and does not make any representations regarding the materials on, such linked third-party websites. If you decide to access or rely on information at linked third-party website, you do so at our own risk. Our terms and conditions, including disclaimers, are more fully set forth in our Terms of Use, Privacy Policy and Terms of Online Sales.

Dr. Thomas Kraft reinforces the management of Resuscitec GmbH

Dr. Thomas Kraft joins the management team of Resuscitec GmbH, which currently consists of Prof. Christoph Benk (CTO) and Jörg Ronde (CFO), effective October 1, 2022. As CEO, the 47-year-old will assume the role of Chairman of the Management Board as well as functional responsibility for the Sales, Marketing and Medical Alliance departments.

“We are pleased to have gained Dr. Thomas Kraft, a proven medtech expert, for our team. In particular, due to his many years of international market experience, he will further accelerate Resuscitec’s growth. Together we will set new standards in the resuscitation market,” says Jörg Ronde, CFO of Resuscitec GmbH.

“Just in Germany, approximately 65,000 people each year die from the consequences of sudden cardiac death. And despite a very well-established rescue and treatment structure, the few survivors often suffer severe brain damage. This is where CARL Therapy, developed in cooperation with the Medical Center –University of Freiburgcomes into play, and our products make us the first provider enabling to implement this therapy in practice. For the treatment of patients requiring resuscitation, this provides a further option along the rescue chain – for the patient’s life. I look forward to continuing to shape this path together with our Resuscitec team,” says Dr. Thomas Kraft, the new CEO of Resuscitec GmbH. 

Dr. Thomas Kraft has been working for 20 years in the field of medical technology and was involved in the management of international medical technology companies for many years with his core competencies in marketing and sales. Most recently, he served as Chief Sales Officer and Managing Director of BIOTRONIK SE & Co. KG, where he was in charge of global sales in more than 100 countries as well as corporate marketing for the cardiology product range.  

During his previous positions at B.Braun Aesculap and Stryker, he was familiar with various therapy and product fields, such as cardiothoracic surgery, orthopedics, neurosurgery, endoscopy and navigation. During this time, he also lived abroad with his family for ten years.

Press contact: Resuscitec GmbH, Engesserstraße 4a, D-79108 Freiburg, press@resuscitec.de                          

< Zurück